Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success
November 27, 2025 | Campaign planning, Protocol consulting, R:SQD, Study rescue, clinical trials
Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.
R:SQD, a groundbreaking recruitment and retention success scoring tool that gives clinical trial sponsors the evidence, insight, and confidence to design and deliver truly participant-centred studies, has launched today.
By blending trial data with patient insights, R:SQD delivers a clear, evidence-based score showing how ready a trial is to attract, recruit, and retain participants, as well as providing tailored recommendations to strengthen engagement and protect trial outcomes.
A new kind of trial health check
R:SQD provides a rapid, evidence-based assessment of how participant-ready a study really is. Its unique scoring system reveals the barriers that may be limiting recruitment or driving dropouts, while expert-driven recommendations help sponsors act early, remove friction, and build trust with participants.
“When recruitment slows or retention drops, it can be hard to see what’s really holding a trial back,” said Stacey Davidson, Head of Strategy and Content at Cuttsy+Cuttsy. “R:SQD cuts through the noise, combining data and empathy to deliver clarity, confidence, and practical next steps. It’s about turning insight into action – helping today’s trials become tomorrow’s breakthroughs.”
Supporting every stage of the trial journey
R:SQD is designed to add value across the full trial lifecycle, whether teams are rescuing an underperforming study, planning a launch, or designing a protocol.
- Study rescue: When a trial is struggling, R:SQD delivers a rapid health check and recovery plan, pinpointing participant-experience fail points and guiding sponsors to regain momentum, protect timelines, and rebuild engagement.
- Campaign planning: Ahead of launch, R:SQD predicts how ready a study is to support participants from day 1. Its readiness score and activation blueprint help leaders allocate resources effectively, identify risks early, and ensure every new trial starts strong.
- Protocol consulting: By reviewing draft protocols through a participant lens, R:SQD highlights where complexity or burden could affect enrolment and retention, helping teams design trials that are not only scientifically robust but also patient-ready and practical in the real world.
Turning data into difference
Unlike traditional analytics platforms, R:SQD blends quantitative insight with human understanding. Its tailored recommendations provide clear, evidence-based actions that make trials more inclusive, efficient, and participant friendly.
“R:SQD reflects our belief that people should be at the heart of every clinical trial,” said Mathew Cutts, Co-Founder and Director of Cuttsy+Cuttsy. “By giving sponsors the tools to see, understand, and address the real barriers to participation, we can help create studies that deliver better experiences and better results.”
Ready to give your trial a health check?
R:SQD is now available to pharmaceutical companies, CROs, and research organisations seeking to strengthen recruitment, retention, and participant engagement strategies.
Discover how R:SQD can put your trial on track for success. Talk to our team.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
A month of insights: Key takeaways from May’s conferences
Explore key insights from some of May’s top healthcare conferences, covering patient engagement, health equity, co-creation, and tech innovation shaping clinical trials.
Cuttsy+Cuttsy and ISPEP highlight key patient insights in new clinical trials report
Explore how Cuttsy+Cuttsy and ISPEP are spotlighting patient engagement in clinical trials through a new global report.
Motivations that matter: Understanding clinical trial participation to create better research
Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to...
Cuttsy+Cuttsy welcomes new team members and celebrates a familiar face returning
Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and the welcome return of former team member Sally as Account Director.
AI and away we go: key insights from Reuters Pharma 2025
AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.
Exciting updates from our content and strategy team
Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.
How is generative AI transforming clinical trials?
Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.
Content for all – how to connect with neurodiverse audiences
Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.
Cuttsy+Cuttsy launches ccura: AI powered, always human
Cuttsy+Cuttsy introduces ccura, an AI-powered healthcare communications platform that blends technology with human expertise to enhance collaboration, streamline workflows, and deliver patient-focused, high-quality solutions with security and compliance at its...
Two Sides of the Same Coin: Patient Engagement vs Patient Involvement
Unpack the difference between patient engagement and patient involvement.